Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
13. August 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Presents Positive Clinical Trial Results at the
2024 SNO/ASCO CNS Metastases Conference
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
12. August 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
08. August 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
25. Juli 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases Leptomeningeal Metastases Programs
at 2024 SNO/ASCO Conference
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
02. Juli 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
07. Juni 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
Plus Therapeutics Announces New Employment Inducement Grants
17. Mai 2024 17:00 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces New Employment Inducement Grants
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
15. Mai 2024 16:15 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
13. Mai 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
09. Mai 2024 11:29 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial